Vol. 20/No. 19 | OncologyLive

New Strategies Generate Optimism for Targeting "Undruggable" KRAS

October 09, 2019

Investigators are starting to make headway in their quest to develop therapies that counteract oncogenic mutations in the KRAS gene, a high-priority target in precision medicine that has long been deemed “undruggable.”

ATOMIC Looks at Immunotherapy in Early-Stage dMMR Colon Cancer

October 07, 2019

Investigators are seeking to determine whether immunotherapy that has been effective in metastatic colon cancers with deficient DNA mismatch repair can be applied to earlier-stage disease, specifically, nonmetastatic stage III colon cancer.

New Data Establish Long-Term Efficacy for 2 Modern Modalities in NSCLC and Melanoma

October 04, 2019

For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.

Merkel Cell Carcinoma Study Matches TMB With Disease Drivers

October 03, 2019

The molecular profile of Merkel cell carcinoma differs depending upon whether the malignancy is driven by ultraviolet light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.

Pancreatic Cancer Is Moving Beyond the Tip of the Treatment Iceberg

October 03, 2019

During an OncLive Peer Exchange®, a panel of pancreatic cancer experts discuss how they select between first- and subsequent-line cytotoxic regimens and strategies they use to reduce toxicity, including dose modifications and alternative combinations. They also provide insights on some of the emerging therapies in clinical trials for advanced pancreatic cancer.

New ASCO System Confronts Lack of EHR Interoperability

October 03, 2019

With the recent launch of a free, open-source system for standardizing the electronic storage of patient records, the American Society of Clinical Oncology hopes to improve information flow across electronic health record platforms and curtail the harms of information blocking by private aggregators and vendors of patient information.

Research Findings Point to Clinical Importance of Clonal Hematopoiesis

October 02, 2019

Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.